John Cole, Co-Founder & Chief Scientific Officer of Research Park startup SimBioSys, joins the podcast! He discusses the breakthroughs his team has created for “transforming decision making and patient experience in cancer care” through a powerful software platform. Tune in…
Each week, staff writer Paul Wood interviews a high-tech difference-maker. This week, meet TUSHAR PANDEY, chief executive officer at SimBioSys Inc. in the University of Illinois Research Park. The company is working on technology to allow doctors and scientists to look…
Background: Although metabolic disfunction is one of the hallmarks of cancer and metabolism-based therapies are a key class of chemotherapeutics, there remains no systematic way to identify metabolism-based targets for therapeutic intervention. Because of this deficiency, metabolism-based therapies offer a…
Background: Over the last decade, there has been incredible progress in HER2-positive breast cancer patients with the adoption of targeted therapies like Trastuzumab and Pertuzumab to complement existing chemotherapies. Increasingly neoadjuvant therapy is the preferred method of therapy as it…
Background: One of the most important sources of variability affecting each patient’s response to neoadjuvant chemotherapy (NACT) is drug and nutrient perfusion, The SimBioSys TumorScope is a computational decision-support system that is designed to predict the flow of drugs and…
Background: Nutrient and drug penetration into any solid tumor are critical determinants of the tumor’s response to treatment. They depend on both the density of microvasculature within the tumor microenvironment, as well as the exchange rates of nutrients between the…
Background: Predictive models of the efficacy of different tumor therapies will provide significant enhancements to current standard of care practices. Predicting a given tumor’s growth and treatment response, however, is an intricate process that requires not only an understanding of…
Background: Success of neoadjuvant chemotherapy (NACT) varies by intrinsic subtype of a patient’s breast cancer (e.g., Normal-like, Luminal A/B, HER2-enriched, Triple Negative). The metabolic rate of a given tumor is implicated in response to chemotherapies, as many act by killing…
Abstract: Spatial organization is a characteristic of all cells, achieved in eukaryotic cells by utilizing both membrane-bound and membrane-less organelles. One of the key processes in eukaryotes is RNA splicing, which readies mRNA for translation. This complex and highly dynamical…
Introduction: Intrinsic breast cancer subtypes (e.g., Normal-like, Luminal A/B, HER2-enriched, Triple Negative) vary in their responsiveness to neoadjuvant chemotherapy (NACT) and are associated with differing long-term prognosis. Expression dis-regulation of critical regulatory pathways partially accounts for variance in cancer phenotype…
SOLUTIONS
- TumorSight Viz
- TumorSight RISK
- PhenoScope
RESOURCES
©SimBioSys